AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04961619 — intervention group
Intervention type: DRUG
Intervention: dabrafenib
Description: There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT04961619 — intervention group
Intervention type: DRUG
Intervention: trametinib
Description: There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT06634849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-4256
Description: Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohort 1-3 will receive 10mg, 20mg \& 40mg.
Study NCT04952857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol 6 lakh IU
Description: vitamin D levels and serum calcium will be assessed at day 3,7, 14.
Study NCT04952857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol 6 lakh IU
Description: vitamin D levels and serum calcium will be assessed at day 3,7, 14.
Study NCT04228549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPADMGT + Nudging
Description: Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
Study NCT05488938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitative Intervention
Description: Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
Study NCT05113940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
Study NCT06108284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Arm (Biphasic cuirass ventilation)
Description: Patients in this arm will be placed on Biphasic cuirass ventilation
Study NCT06430892 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment
Study NCT05443022 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
Study NCT05443022 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of Photobiomodulation
Description: The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
Study NCT05631132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BAL + PAP
Description: May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
Study NCT06394973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T4090 0.2%
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Study NCT06457126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique
Description: Phase 1: Non-concurrent multiple baseline design A-B design where the ATT (B) is introduced sequentially across participants. ATT and baseline (A) will be alternated on a weekly basis.~Phase 2: Alternating treatment design where an active (B) and passive (C) version of the ATT are rapidly and frequently alternative within the same participant on a weekly basis (e.g., A-B-A-C-A or A-C-A-B-A).
Study NCT06394973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T4090 0.3%
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Study NCT06394973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhopressa®
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Study NCT04988230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
Study NCT06216340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: 10mg of Henagliflozin and diet-exercise therapy
Study NCT06216340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and diet-exercise therapy
Study NCT04988230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
Study NCT05819229 — intervention group
Intervention type: DRUG
Intervention: Oral antibiotic therapy
Description: Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days.
Study NCT06263712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program (ASSIP)
Description: The Attempted Suicide Short Intervention Program (ASSIP) is a specific therapy for patients with a suicide attempt in their biography. The brief therapy ASSIP consists of three to four sessions of approximately 50 minutes each.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her\*his personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years.
Study NCT06263712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care plus resource interview group (STAR)
Description: The standard of care plus resource interview group (STAR) will be offered a clinical interview, a risk assessment, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the patient is asked to name her\*his resources, describe them, and give examples.
Study NCT05670106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
Study NCT05670106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive/best standard of care (BS/BSOC)
Description: Best supportive/best standard of care as defined by the local investigator
Study NCT05088148 — intervention group
Intervention type: OTHER
Intervention: . Pesticide and Pharmaceutical analysis
Description: Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
Study NCT04996693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Imaging on Scanner with Spectral Imaging Capabilities
Description: Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
Study NCT04996693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)
Description: Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
Study NCT04996693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)
Description: Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
Study NCT05187169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VS-6766
Description: Dual RAF/MEK inhibitor
Study NCT04751643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)
Description: Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation
Study NCT04751643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual treatments in intensive care unit according to the current state of knowledge
Description: Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
Study NCT04751643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatments in intensive care unit according to the current state of knowledge
Description: Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
Study NCT05936086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
Study NCT05936086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
Study NCT05936086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
Study NCT05936086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
Study NCT05936086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (CSA)
Description: Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
Study NCT06039735 — intervention group
Intervention type: OTHER
Intervention: Chemotherapy and/or autologous hematopoietic stem cell transplantation
Description: Didn't interfere patients' treatment plan. Patients with chemotherapy (lenalidomide,bortezomib and dexamethasone) and/or autologous hematopoietic stem cell transplantation(ASCT) which is assessed by clinical doctors and only conventional treatments were used
Study NCT05234567 — intervention group
Intervention type: BIOLOGICAL
Intervention: Asfotase Alfa
Description: All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged \< 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
Study NCT06238388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 Injection
Description: A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
Study NCT06561789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functionalized Nano ᵦ tricalcium phosphate particles
Description: The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
Study NCT06561789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nano ᵦ tricalcium phosphate particles
Description: The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
Study NCT06561789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium fluoride mouth wash
Description: The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
Study NCT04742686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme. Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
Study NCT06563271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol 50 Mg/mL Solution for Injection
Description: Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Study NCT06563271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 100 MG/ML Solution for Injection
Description: Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Study NCT06563271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 10 Mg/mL Solution for Injection
Description: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Study NCT06563271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
Study NCT04349475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention Omega 3 Supplementation
Description: Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)
Study NCT04349475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Safflower Oil
Description: Participants will consume 2.5g of a Safflower oil supplement daily
Study NCT05670106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
Study NCT05599425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Healthy Living Education
Description: 24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change
Study NCT05599425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Healthy Living Education
Description: 24-session healthy living education program
Study NCT05302752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic phrenic nerve stimulation
Description: The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated.
Study NCT04714112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
Study NCT04714112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
Study NCT05162235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality-assisted localization of solitary pulmonary nodule
Description: In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
Study NCT04783207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure
Description: Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
Study NCT04783207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel containing only excipients. 4 soft-gels to be taken daily
Study NCT05308147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: First Reference product
Description: Dextrose (containing 25 grams of carbohydrates)
Study NCT05308147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Second Reference product
Description: Dextrose (containing 25 grams of carbohydrates)
Study NCT05308147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Third Reference product
Description: Dextrose (containing 25 grams of carbohydrates)
Study NCT05308147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: First Concept product
Description: Infant Formula (containing 25 grams of carbohydrates)
Study NCT05308147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Second Concept product
Description: Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
Study NCT06169085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: Oral
Study NCT05308147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Third Concept product
Description: Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
Study NCT05332444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: susceptibility-guided tailored therapy (Group A)
Description: Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
Study NCT05332444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guidelines-recommended empiric therapy (Group B)
Description: bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
Study NCT04166630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Electrical Stimulator
Description: Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
Study NCT04643067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPG-818 low dose
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
Study NCT04643067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPG-818 mid dose
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
Study NCT04643067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPG-818 high dose
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.